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Abstract 
S-nitrosoglutathione (GSNO) at low concentration inhibits platelet aggregation without 
causing vasodilation, suggesting platelet-selective nitric oxide delivery. The mechanism of 
this selectivity is unknown, but may involve cell surface thiol isomerases, in particular 
protein disulphide isomerase (csPDI) (EC 5.3.4.1). We have now compared expression and 
activity of csPDI on platelets, endothelial cells and vascular smooth muscle cells, and the 
dependence on thiol isomerase activity of these cell types for NO uptake from GSNO.  
 
csPDI expression was measured by flow cytometry and its reductase activity using the 
pseudosubstrate dieosin glutathione disulphide. This activity assay was adapted and validated 
for 96-well plate format. Flow cytometry revealed csPDI on all three cell types, but 
percentage positivity of expression was higher on platelets than on vascular cells. Consistent 
with this, thiol isomerase-related reductase activity was higher on platelets (p < 0.01), and 
cellular activation (with either phorbol myristate acetate or ionomycin) increased csPDI 
activity on both platelets and smooth muscle cells, but not on endothelium. Intracellular NO 
delivery from GSNO was greater in platelets than in vascular cells (P < 0.002), and was more 
sensitive to thiol isomerase inhibition using phenylarsine oxide (P < 0.05).  
 
Increased surface thiol isomerase activity on platelets, compared with cells of the vascular 
wall, may explain the platelet-selective actions of GSNO and help define its antithrombotic 
potential.  
 
Short Title: Thiol isomerase-mediated NO delivery to platelets and vascular cells 
Keywords: Platelets; endothelial cells; smooth muscle cells; S-nitrosoglutathione (GSNO); 
thiol isomerases; protein disulphide isomerase (PDI) 
3 
 
1. Introduction 
 
Thiol isomerases comprise the thioredoxin superfamily of oxidoreductases, characterised by 
the presence of one or more thioredoxin-like domains containing the CXXC motif [1]. 
 
Over the last decade thiol isomerases located at the cell surface, most prominently protein 
disulphide isomerase (EC 5.3.4.1), have emerged as regulators of platelet function [2-6], and 
of tissue factor activity [7-9]. Cell surface protein disulphide isomerase (csPDI) influences 
both fibrin generation and platelet thrombus formation in mouse models (8), confirming that 
csPDI is relevant to in vivo haemostatic regulation. 
 
A further cellular action of csPDI relevant to haemostasis and vascular regulation is to 
facilitate delivery across the plasma membrane of nitric oxide (NO) signalling [10,11]. Our 
own previous studies have shown that csPDI is required for the delivery into platelets of a 
range of NO redox derivatives [12] and that during this process csPDI undergoes thiol 
modification [13]. NO supplementation by means of donor drugs is a potentially useful 
antithrombotic strategy in patients suffering from cardiovascular disease due to endothelial 
dysfunction [14], and the anti-thrombotic action of S-nitrosothiols (RSNOs) has attracted 
particular interest because certain of these compounds show evidence of platelet-selective 
action [15]. For example, administration of low doses of S-nitrosoglutathione (GSNO) to 
human patients produced platelet inhibition without significant vasodilation [16]. This 
suggests preferential NO signalling into platelets, perhaps via differences in GSNO 
metabolism between platelets and cells of the blood vessel wall. Because of the role of csPDI 
in NO delivery, it is important to establish whether there are differences in the expression or 
activity of this enzyme between platelets and vascular cells. 
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PDI displays both oxidase and reductase, as well as thiol isomerase activity [1], however 
since the mechanism of its S-denitrosation of GSNO involves electron donation by the active 
site thiols [17], measurement of its reductase activity is most relevant in this context. A novel 
fluorescent assay sufficiently sensitive to measure csPDI reductase activity has recently been 
published [18] and we have therefore used this technique, adapted in 96 well plate format, to 
compare csPDI on platelets, endothelial cells and vascular smooth muscle cells. Our aim was 
to identify differences in csPDI expression between the cell types and to determine whether 
preferential NO delivery into platelets might be explained on this basis. 
 
2. Materials and Methods 
 
2.1 Chemicals  
 
DAF-FM (4-amino-5-methylamino-2’7’ difluorofluorescein) diacetate was obtained from 
Molecular Probes (Paisley, UK). GSNO (S-Nitroso-L-glutathione) was obtained from Alexis 
Biochemicals (Exeter, UK). Mouse anti-PDI antibody (1D3) conjugated R-Rhycoerythrin 
(PE) and PE-labeled isotype-matched control antibody (mouse IgG1) were obtained from 
Assay Designs (Exeter, UK). Live/Dead Fixable Dead Cell Stain Kits was obtained from 
Invitrogen (Paisley, UK). BCA protein assay kit was obtained from Thermo Scientific 
(Northumberland, UK).  PD-10 Desalting columns were obtained from GE Healthcare 
(Buckinghamshire, UK). Dulbecco’s Phosphate Buffered Saline (D-PBS and Fetal bovine 
serum (FBS) were obtained from Lonza Workingham Ltd (Slough, UK). All other chemicals 
were purchased from Sigma (Poole, UK). 
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2.2 Preparation of dieosin glutathione disulphide (di-E-GSSG) 
  
The synthetic pseudosubstrate dieosin glutathione disulphide (Di-E-GSSG) was generated by 
incubation of GSSG (100 M) with a 10-fold molar excess of eosin isothiocyanate (1 mM) in 
phosphate buffer (100 mM potassium phosphate and 2mM EDTA, pH 8.8) overnight at room 
temperature as previously described [18] with minor modification. One hundred microliter 
aliquots were taken and passed down a PD-10 desalting column (Sephadex G-25) using 0.1 
M potassium phosphate buffer, pH 7.0, containing 2 mM EDTA, and one millilitre aliquots 
were collected. The eluted fractions were tested for fluorescence increase before and after the 
addition of DTT (10 mM) by monitoring at 545 nm with excitation at 525 nm. All fractions 
showing at least 10-fold increase in fluorescence were pooled and stored at -20C.  
 
2.3 Preparation of washed platelets 
 
Washed platelets were prepared as previously described [12]. Briefly, whole blood (20 ml) 
was obtained with informed consent, according to the Declaration of Helsinki, from healthy 
volunteers and drawn into 25 ml container containing 3 ml of acid citrate dextrose. Platelet-
rich plasma (PRP) was separated from other cellular components of blood by centrifugation 
twice at 170 g for 10 min, keeping the upper layer each time. PRP was acidified with 0.5 M 
citric acid to pH 6.2-6.5, and prostaglandin E1 (1.5 M) and apyrase (2 units/ml) were added 
to prevent aggregation during subsequent centrifugation at 1000 g for 12 min. The platelet 
pellet was then resuspended in 1 ml HEPES-buffered saline (HBS) containing 140 mM NaCl, 
2.7 mM KCl, 5mM Glucose and 10 mM HEPES (pH 7.3) and loaded on to a Sepharose 2B 
column (1.45 x 5.0 cm). The platelet fraction was eluted with HBS and the platelet count was 
adjusted to 10
8
/ml before use.  
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2.4 Cell culture 
 
Human coronary artery endothelial cells (HCAEC), human coronary artery smooth muscle 
cells (HCASMC), and their culture mediums were purchased from PromoCell (Heidelberg, 
Germany), and cultured according to manufacturer’s instructions. Cells were passaged using 
a solution of 0.125% trypsin and 0.02% EDTA in Dulbecco’s PBS (D-PBS). Experiments 
were performed after 3-5 passages, and the cell count adjusted to 10
5
 / ml before use. 
 
2.5 Assay of PDI reductase activity 
 
Reductase activity of cell surface thiol isomerases was monitored in a 96-well microplate 
fluorescence assay. Authentic PDI (10-100 nM) was incubated with Di-E-GSSG (150 nM) in 
HBS containing 5 M DTT (PDI assay buffer). The increase in fluorescence was monitored 
at excitation and emission wavelengths (Ex 510nm / Em 550nm) which were optimised for 
the microplate reader (Gemini EM, Molecular Devices, Wokingham UK). The same protocol 
was used to monitor reductase activity of csPDI on variable numbers of platelets (1 – 16 x 
10
7
 per well). In further experiments, platelets (2 x 10
7
/well) were incubated with the thiol 
isomerase inhibitor phenylarsine oxide (PAO) (12.5 - 100 M) at 370C for 30 min before 
addition of Di-E-GSSG (150 nM). To compare the reductase activity of csPDI in the different 
cells, cellular total protein was measured in parallel using BCA kit according to the 
manufacturer’s protocol, and results normalized to the amount of cell protein. To determine 
the effect of cell activation, the three cell types were incubated with phorbol myristate acetate 
or ionomycin at concentrations of 1-100 M, and cell surface thiol isomerase activity was 
then monitored over 45 min, as described above.   
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2.6 Flow cytometry analysis 
 
Cultured cells were collected by trypsinization and washed twice in cold D-PBS by 
centrifugation at 150 g for 6 min. The density of washed cells and isolated platelets was then 
adjusted to 2 x 10
7
/ml with D-PBS. 100 µl of the adjusted cells were incubated with 1 l of 
near-IR fluorescent reactive dye provided with Live/Dead Fixable Dead Cell Stain Kits for 30 
min to distinguish the live and dead cells. The dye-loaded HCAEC and HCASMC were then 
washed twice with D-PBS by centrifugation at 150 g for 6 min and the dye-loaded platelets 
were finally washed in D-PBS containing 5 mM EDTA by centrifugation at 1000 g for 6 min. 
Cells were then resuspended in D-PBS containing 2% FBS and incubated with PE-PDI 
antibody (1:50 dilution) on ice for 30 min.  PE-labeled isotype-matched control antibody 
(mouse IgG1) was used in parallel to set the fluorescence threshold for primary antibody. The 
expression of csPDI on the cells was analyzed in a CyAn ADP Analyzer (DakoCytomation, 
Denmark). Forward (FSC) and side scatter (SSC) were set at logarithmic gain and triggering 
was set at FSC. Live cells were gated and analyzed. 
In separate experiments, platelets were subjected to the trypsinisation protocol described 
above for detachment of vascular cells, and the effect of this on csPDI expression was 
assessed to see whether expression might be affected by differences in cell preparation 
procedure. 
 
2.7 Measurement of the entry of NO× (reactive nitrogen species) into cells 
 
DAF-FM diacetate, a membrane-permeant fluorescent probe, was used for detecting 
intracellular NOx as previously described [12]. Cells were suspended in HBS and then 
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incubated with DAF-FM diacetate (5 M) at 370C for 30 min. The DAF-FM-loaded platelets 
were then separated from free probe on a Sepharose 2B column. Excess DAF-FM was 
separated from HCAEC and HCASMC by centrifugation. S-Nitroso-L-glutathione (GSNO) 
at concentrations of 10
-7
 – 10-3 M was then added to the cells (105 /mL) in PDI assay buffer.  
Fluorescence intensity at 515 nm with excitation at 480 nm was measured over 30 min using 
the microplate reader. To take account of higher fluorescence in the larger cells, data for each 
cell type were expressed as a percentage of the maximum value, obtained using 1 mM 
GSNO. In experiments to determine the role of PDI in NO delivery, cells were pre-incubated 
with 100 µM phenylarsine oxide (PAO), a thiol isomerase inhibitor, at 37
0
C for 30 min 
before addition of 1 mM GSNO.   
 
2.8 Statistical analysis 
 
All data are expressed as mean ± SEM. One-way ANOVA was used for difference between 
data groups and dose response curves were compared using two-way ANOVA followed with 
Bonferroni post-hoc correction for multiple comparisons. Differences were considered 
significant when p < 0.05. 
 
3. Results 
 
3.1 Reductase activity of authentic PDI and platelet cell surface thiol isomerases 
 
The fluorescent PDI reductase assay employing Di-E-GSSG, first described by Raturi and 
Mutus [18] was successfully adapted for use in 96 well microplate format, as shown by 
reproducible and dose dependent activity of authentic PDI (Fig 1A) and of cell surface thiol 
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isomerase on platelets (Fig 1B), which was inhibited in a dose dependent manner by the thiol 
isomerase inhibitor PAO (Fig 2).  
 
3.2 Comparison of csPDI expression and thiol isomerase activity on platelets, 
endothelial cells and vascular smooth muscle cells 
 
csPDI was detected by flow cytometry on platelets, HCAEC and HCASMC (Fig 3A). Both 
endothelial and smooth muscle cells showed more variable expression than platelets (Fig 3B) 
and when compared in terms of percentage positive cells, the level of the expression on 
platelets was significantly higher than on HCAEC and HCASMC (Fig 3C, P < 0.01). Platelet 
csPDI expression was unchanged by exposure to the trypsin reagent used to detach vascular 
cells from culture flasks (data not shown), indicating that our results were not due to 
differences in cell preparation prior to flow cytometric analysis. Consistent with this, csPDI 
reductase activity was significantly greater on platelets than on HCAEC and HCASMC (P < 
0.01), when results were normalized for cell protein, with platelets showing approximately 6- 
fold and 15- fold higher activity than HCAEC and HCASMC, respectively (Fig 4). To take 
into account the effect of differences in surface area between the cell types, we measured the 
number of cells required to provide an equal amount (1 g) of protein as 68000, 380 and 540 
for platelets, HCAEC and HCASMC, respectively. Estimates of platelet surface area range 
from 14 m2 [19] to 22 m2 [20]. The diameter of trypsinised HCAEC and HCASMC ranges 
from 10 – 25 m (personal communication, Promocell, Heidelberg), so taking a mean value 
of 17.5 m, and assuming a spherical shape, for these cells, their average surface area can be 
estimated as 962 m2. Taking this value, and a mean platelet value of 18 m2, it can be 
calculated that the excess of platelet surface area in our experiments was 3.3-fold compared 
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with HCAEC and 2.4-fold compared with HCASMC. Thus it appears that discrepancy in cell 
surface area does not fully account for the higher csPDI activity seen in platelets. 
In experiments to determine the effect of cell activation on csPDI activity, stimulation with 
PMA and ionomycin significantly increased the reductase activity on platelets and HCASMC 
(p < 0.01), but no changes were detected on HCAEC (Fig 5A, 5B).  
 
3.3 GSNO mediated NO× entry into platelets, HCAEC and HCASMC 
 
Compared with both HCAEC and HCASMC, intracellular NOx delivery from GSNO was 
greater in platelets (P < 0.001) (Fig 6A). Because of differences in absolute DAF-FM 
fluorescence values between the different cell types, NOx delivery was normalized to the 
percentage of maximal signal obtained following exposure to a GSNO concentration of 
1mM. The results showed a greater proportional increase in platelets than in the other cell 
types, indicating that platelets are better able than HCAEC and HCASMC to receive NOx at 
low concentrations of GSNO. When csPDI was blocked using PAO, the percentage inhibition 
of DAF-FM fluorescence following GSNO exposure was higher for platelets than for 
endothelial cells or smooth muscle cells (P < 0.05) (Fig 6B), indicating that platelets rely 
more heavily on csPDI for NOx delivery. 
 
4. Discussion  
 
We have established techniques to measure the expression and reductase activity of surface 
thiol isomerases on different cell types. PDI is a prominent member of this surface 
population, however the Di-E GSSG assay and the PAO inhibitor used in our experiments are 
non-specific, so the functional activity detected may derive from other isomerases in addition 
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to PDI. Flow cytometric determination of csPDI showed the highest percentage positivity on 
platelets, whereas both vascular smooth muscle and endothelial cells displayed a wider 
spread of expression, with some cells showing high activity but the majority being negative. 
Functionally active thiol isomerase was higher on platelets than on either of the two vascular 
cell types, and this heightened activity on platelets was not fully accounted for by increased 
availability of cell surface area. In addition, platelets showed an increase in thiol isomerase-
dependent NO delivery.  
 
The presence of csPDI has been documented on a variety of cell types [21] however the 
processes governing localisation of PDI to the cell surface are not fully determined. In 
hepatocytes PDI secretion is mediated by microtubular activity and attachment to the plasma 
membrane appears to involve electrostatic interactions.  Secreted PDI continues to display the 
KDEL endoplasmic reticulum (ER) retention signal and it is speculated that secretion may 
arise via leakage from a salvage pathway whose function is to recycle proteins to the ER [22].  
 
Several groups have shown that PDI is present inside endothelial cells and that it is up-
regulated under conditions of hypoxia [22-25], during which it becomes a target for S-
nitrosylation [26]. It is not yet clear whether PDI becomes upregulated on the cell surface in 
hypoxia. Endothelial cells in culture also express PDI on their exofacial surface in a 
punctuate distribution, possibly reflecting a concentration at cellular projections [9,27]. This 
csPDI regulates the adhesive properties of both thrombospondin [27] and of its binding 
partner integrin αvβ3 [28], and in addition catalyses transnitrosation of endothelial target 
molecules [29]. In contrast, experiments performed using mouse models of thrombus 
formation indicate that, in vivo, csPDI is not expressed on the endothelial surface of the 
unperturbed vessel wall, but that it accumulates rapidly following vascular injury [30,31]. 
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The observed kinetics of csPDI accumulation under such circumstances suggest that it 
derives from both disrupted vascular cells and also from platelets adhering at the site of 
injury.  csPDI has been detected on endothelial cells by flow cytometry [9] and in one study 
[28] the percentage of endothelial cells showing positivity for csPDI was much higher than 
our observed results. This discrepancy may arise from our use of primary cells in contrast to 
the EA.hy926 cell line (derived from fusion of endothelial and lung carcinoma cells) used in 
the earlier study.  
 
PDI is present inside vascular smooth muscle cells and shows a shift to the membrane 
fraction (detectable by both western blotting and increased refolding activity) following cell 
stimulation with angiotensin II. Under these conditions membrane-associated PDI appears to 
co-localise with and regulate the activity of NADPH oxidase [32]. In similar fashion, 
activation of platelets is associated with increased secretion of both PDI [33] and a range of 
other thiol isomerases which go on to modulate various aspects of platelet function [34,35]. It 
should be noted, however, that csPDI is also present on the surface of resting platelets 
[33,36], so activation is not required for csPDI to be displayed. We found that cell activation 
with PMA and ionomycin brought about an increase in thiol isomerase activity on both 
platelets and smooth muscle cells, however this effect was not apparent in endothelial cells. 
PMA and ionomycin were deliberately chosen in order to stimulate generic intracellular 
signaling pathways (involving protein kinase C and intracellular calcium, respectively), so 
the variation in response between the cell types was not due to differential expression of 
particular agonist receptors. Interestingly, in hepatocytes the extracellular secretion of PDI 
was actually reduced by cellular stress in the form of tunicamycin treatment or heat shock 
[22], so it is clear that the effects on surface thiol isomerases of cell stress / stimulation are 
not uniform across cell types.  
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Our measurements of cell surface reductase activity were made using a 96 well plate 
adaptation of the original method described by Raturi and Mutus [18] which allowed the use 
of small sample volumes. Our results clearly showed that platelets possess a more active 
surface, in this respect, than endothelial and smooth muscle cells.  In parallel, the delivery of 
NOx into platelets was greater than into the other cell types, and the degree of thiol 
isomerase-dependence was greatest for platelets, as reflected in the loss of NO delivery 
brought about by the thiol isomerase inhibitor PAO. In these experiments, DAF-FM was used 
to detect the arrival of NO-related signalling inside cells. This fluorescent probe measures a 
range of NO / oxygen reaction products, therefore it is not possible to specify the identity of 
the NO derivative which is delivered. The NO donor used for these experiments was GSNO, 
so these results are relevant to the previously described clinical data indicating platelet-
selective action of this agent [16].  
 
Research into the mechanisms by which cells take up NO from impermeable donor 
compounds such as GSNO has highlighted two major pathways: NO release in the proximity 
of the plasma membrane by denitrosating enzymes (such as csPDI) (10-12), and 
transnitrosation to cysteine followed by import of intact S-nitrosocysteine via the L-AT 
family of amino aid transporters [37]. We have previously argued that the former mechanism 
is more important in platelets [15] and the results of the present study are consistent with this 
hypothesis. We suggest that the platelet selective actions of GSNO result from platelet csPDI 
metabolising GSNO more rapidly than the endothelial lining of the blood vessel wall, 
allowing anti-platelet action of NO to occur without significant NO delivery to vascular 
smooth muscle to bring about vasodilation. The emerging evidence of PDI involvement in 
various components of haemostasis / thrombosis suggests that differential csPDI availability 
14 
 
may have wider relevance for vascular biology which goes beyond nitric oxide delivery 
alone. 
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Figure Captions 
Figure 1. 96-well microplate fluorescence assay for PDI reductase activity. Di-E-GSSG 
(150nM) was incubated with serially diluted authentic PDI (0 to 160 nM) (A) and washed 
human platelets (0 to 16 x 10
7
 per well) (B). Fluorescence was monitored over 120 min with 
excitation at 510 nm and emission at 550 nm, and the initial rate of change (relative 
fluorescence unit per min) was calculated. Samples were assayed in triplicate and data 
represent mean ± SEM from 3 separate experiments. 
 
Figure 2. Inhibition of platelet csPDI reductase activity by PAO. Washed platelets were 
pre-incubated with PAO (12.5 to 100 µM) at 37
0
C for 30 min before addition of Di-E-GSSG 
(150nM) and measurement of rate of change of fluorescence (Ex 510nm / Em 550nm). 
Values are expressed as percentage inhibition vs control, and data represent mean ± SEM 
from 3 separate experiments, each performed in triplicate. 
 
Figure 3.  Expression of csPDI on HCAEC, HCASMC and human platelets. (A) Washed 
platelets and vascular cells were characterized by forward (FSC) and side scatter (SSC). The 
gated cells (R1) were analyzed. (B) Surface staining of the cells with PE-labelled isotype-
matched control antibody (IgG1) (red) and anti-PDI antibody (blue). (C) The anti-PDI 
antibody positive cells were quantified. Percentage positivity in HCAEC and HCASMC was 
significantly lower compared with platelets (** P < 0.01). Data represent means ± SEM from 
3 separate experiments. Values are expressed as a percentage of positivity in 10,000 cells.  
 
Figure 4. Comparison of csPDI reductase activity on HCAEC, HCASMC and human 
platelets. Vascular cells (10
5
/ml) and platelets (10
8
/ml) were incubated with Di-E-GSSG 
(150nM) and csPDI activity was measured by monitoring change in fluorescence (Ex 510 nm 
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/ Em 550 nm) for 30 min. Values are corrected for amount of cell protein to take account of 
differences in cell size and number. As an internal control, maximum available fluorescence 
was measured in parallel by incubating Di-E-GSSG with10 mM DTT, and results were then 
expressed as a percentage of this maximum value. Data represent mean ± SEM from 3 
separate experiments, each performed in triplicate. ** P < 0.01.  
 
Figure 5. Effects of cellular activation on csPDI reductase activity in HCAEC, 
HCASMC and human platelets. Following addition of PMA (A) and ionomycin (B) (both 
1-100 µM), vascular cells (10
5
/ml) and platelets (10
8
/ml) were incubated with Di-E-GSSG 
(150nM) for 30 min to measure change of fluorescence (Ex 510 nm / Em 550 nm). Results 
are expressed as percentage increase compared with untreated control, and data represent 
mean ± SEM from 3 separate experiments, each performed in triplicate. Both PMA and 
ionomycin increased csPDI activity in HCASMC and platelets however no increase was 
observed in HCAEC.  This difference was significant (p < 0.01) when analyzed by Two-way 
ANOVA followed by Bonferroni post-hoc correction for multiple comparisons. 
 
Figure 6. Intracellular NO delivery from GSNO. (A) DAF-FM diacetate - loaded vascular 
cells (10
5
/ml) and platelets (10
8
/ml) were incubated with GSNO (10
-7
 – 10-4 M) at 370C for 
15 min, and entry of NO-related signalling was measured by increase in fluorescence 
intensity (Ex 495 nm / Em 550 nm). To take account of differences in absolute fluorescence 
values between the different cell types, parallel measurements of maximum fluorescence 
(defined as response to 10
-3
 M GSNO) were made and responses reported as percentage of 
this maximum value.  Intracellular NO delivery was greater in platelets, compared with both 
HCAEC and HCASMC (P < 0.001), whereas there was no significant different between 
HCAEC and HCASMC. Data were analyzed by Two-way ANOVA followed by Bonferroni 
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post-hoc correction for multiple comparisons. (B) To determine the PDI dependence of NO 
delivery in each cell type, fluorescence changes in response to 1 mM GSNO were measured 
following pre-incubation with PAO (100 uM) for 30 min. Values are expressed as percentage 
inhibition vs untreated controls. Data represent mean ± SEM from 3 separate experiments, 
each performed in triplicate. (* p < 0.05, ** p < 0.01 by One-way ANOVA followed by 
Bonferroni post-hoc correction for multiple comparisons). 
 
 
  
 
 
 
 
 
 
 
 
